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Background: Na/K-ATPase (NKA) is inhibited by perillyl alcohol (POH), a monoterpene used in the treatment of
tumors, including brain tumors. The NKA α1 subunit is known to be superexpressed in glioblastoma cells (GBM).
This isoform is embedded in caveolar structures and is probably responsible for the signaling properties of NKA
during apoptosis. In this work, we showed that POH acts in signaling cascades associated with NKA that control cell
proliferation and/or cellular death.
Methods: NKA activity was measured by the amount of non-radioactive Rb+ incorporation into cultured GBM cell
lines (U87 and U251) and non-tumor cells (mouse astrocytes and VERO cells). Cell viability was measured by lactate
dehydrogenase levels in the supernatants of POH-treated cells. Activated c-Jun N-terminal Kinase (JNK) and p38
were assessed by western blotting. Apoptosis was detected by flow cytometry and immunocytochemistry, and the
release of interleukins was measured by ELISA.
Results: All four cell types tested showed a similar sensitivity for POH. Perillic acid (PA), the main metabolite of
POH, did not show any effect on these cells. Though the cell viability decreased in a dose-dependent manner when
cells were treated with POH, the maximum cytotoxic effect of PA obtained was 30% at 4 mM. 1.5 mM POH activated
p38 in U87 cells and JNK in both U87 and U251 cells as well as mouse astrocytes. Dasatinib (an inhibitor of the
Src kinase family) and methyl β-cyclodextrin (which promotes cholesterol depletion in cell membranes) reduced
the POH-induced activation of JNK1/2 in U87 cells, indicating that the NKA-Src complex participates in this mechanism.
Inhibition of JNK1/2 by the JNK inhibitor V reduced the apoptosis of GBM cells that resulted from POH administration,
indicating the involvement of JNK1/2 in programmed cell death. 1.5 mM POH increased the production of interleukin
IL-8 in the U251 cell supernatant, which may indicate a possible strategy by which cells avoid the cytotoxic effects of POH.
Conclusions: A signaling mechanism mediated by NKA may have an important role in the anti-tumor action of POH in
GBM cells.
Keywords: Na/K-ATPase, Perillyl alcohol, JNK, U87 and U251 glioma cells* Correspondence: burth@vm.uff.br
2Departamento de Biologia Celular e Molecular, Instituto de Biologia,
Universidade Federal Fluminense, Niterói, RJ, Brazil
Full list of author information is available at the end of the article
© 2015 Garcia et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Garcia et al. Molecular Cancer  (2015) 14:105 Page 2 of 14Background
Na/K-ATPase (NKA) is a membrane-associated protein
complex found in animal cells that couples the energy
stored in ATP molecules to the transport of Na+ and K+
across cell membranes. This transport produces an elec-
trochemical gradient that is essential for maintaining the
cell membrane potential and the excitable activities of
muscle and nerve cells [1-3]. Apart from its function as an
ion pump, NKA is also a signal transducer. This enzyme
interacts with different signaling proteins in caveolae, in-
cluding Src tyrosine kinase, PKC, PKA, PI3K, caveolins
and EGFR [4-8]. This set of proteins associated with NKA
is called the signaling complex or signalosome, which is
restricted to caveolae [5,7-12].
The activation of the NKA-Src complex is the starting
point for signaling after the binding of cardiac glycosides
to NKA. Ouabain binding regulates the interaction between
NKA and caveolin, which stimulates the cytoplasmic Src
kinase. Activated Src transactivates EGFR, which recruits
adapter proteins, leading to further activation of the
Ras-Raf-MAPK cascade [9,12]. The three major members
of the mitogen-activated protein kinase family (MAPKs)
are extracellular signal-regulated kinase (Erk), c-jun N-
terminal kinase (JNK) and p38. In general, activated Erk
controls cell proliferation and differentiation. On the other
hand, JNK and p38 signaling promotes cell proliferation,
invasion, survival, migration, growth arrest and apoptosis
[13]. However, the intracellular signaling triggered by car-
diac glycosides depends on the cell type, exposure time
and drug concentration [14,15].
The effects of cardiac glycosides on the activity of
NKA and the use of these glycosides in the therapy of
cardiovascular diseases have been broadly publicized.
However, some studies have shown low mortality rates
in cancer patients treated with cardiac glycosides, par-
ticularly in women with breast cancer [16]. The fact that
NKA also acts as a signal transducer has sparked new
interest in the properties of cardiac glycosides as anti-
cancer drugs [17]. Moreover, NKA activity is already
changed during the early stages of tumorigenesis, even
before morphological evidence can demonstrate the
presence of tumors [18,19]. Some studies have suggested
that the suppression or stimulation of NKA isoforms,
mainly α1 and α3, depends on the type of cancer in
question. For example, the expression of NKA α1 is
stimulated in cancers of the brain, lung and skin or
inhibited in bowel and bladder cancers. On the other
hand, NKA α3 is mainly stimulated in colon and rectal
cancers [20,21]. Several in vivo and in vitro studies have
confirmed these observations, and substances based on
the structures of cardiac glycosides have already been
used in clinical trials for cancer treatment [22-24].
These findings suggest that new anticancer agents that
act on NKA can be developed, as this enzyme may bean important target for anticancer therapy [25]. This
is especially the case for the α1 subunit of NKA in
apoptosis-resistant glioblastoma cells [26,27].
The importance of NKA in anticancer therapy has also
been suggested using compounds unrelated to the car-
diac glycoside structure, such as the monoterpene peri-
llyl alcohol (POH) [28,29]. POH is found in essential
oils from various plants that have chemopreventive and
chemotherapeutic activities against different tumors,
including glioblastomas (GBM), the most common and
malignant human brain tumor [30-33]. GBM is character-
ized as a high-grade astrocytoma (grade IV) that presents
an infiltrating ability and the absence of limitation. Our
previous studies conducted in both membrane prepara-
tions and in glioblastoma cells have shown that the POH
is an NKA inhibitor with higher specificity for the α1 sub-
unit than the predominant brain isoforms (α2 and α3)
[28]. This fact may be interesting because this isoform was
described in the literature as a mediator of signal trans-
duction mechanisms [26]. Due to the involvement of
NKA in numerous cellular functions, changes in the activity
and expression of this enzyme may be related to the patho-
genesis of many diseases, making this enzyme a powerful
therapeutic target. Therefore, our aim was to determine
whether POH might act on signaling cascades modulated
by NKA, thus controlling cell proliferation and/or death.
Materials and Methods
Cell culture conditions
Astrocyte primary cultures were prepared from newborn
Swiss mice following the procedure previously described
by Gomes et al. (1999) [34]. U87 and U251 cell lines
(from human GBM) and VERO cell lines (from African
green monkey kidneys) were cultured with DEMEM or
DMEM-F12 (Invitrogen) supplemented with 10% heat-
inactivated fetal bovine serum (Invitrogen) and antibi-
otics (100 U/mL penicillin, 100 U/mL streptomycin-
Invitrogen) at 37°C in a humid atmosphere containing
5% CO2. The cells were grown to semi-confluence in
plates containing 6 or 24 wells.
Na/K-ATPase assay in intact cells
The NKA assay in cell culture was based on the meas-
urement of non-radioactive Rb+ incorporation according
to Gill et al. (2004) [35]. After the samples were digested
with nitric acid, Rb+ measurements were done in an in-
ductively coupled plasma-optical emission spectrometer
(Jobin–Yvon), as described previously [28]. Different
concentrations of POH, 4 mM perillic acid (PA) and
0.5 mM ouabain were added to specific wells. These
drugs were obtained from Sigma. POH and PA were dis-
solved in dimethyl-sulfoxide (DMSO) and used in the
cell treatments at maximum concentrations of 0.1%.
After 30 min incubation at 37°C, the cells were washed
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lysis solution (0.15% SDS) was added to each well. The
NKA activity was expressed as the difference between
Rb+ incorporation in the absence or presence of 0.5 mM
ouabain.
Evaluation of cytotoxicity
We used the Cytotoxicity Detection Kit (Doles) to quan-
titate cell death. This assay involves a colorimetric quan-
tification of cell death based on the measurement of the
activity of lactate dehydrogenase (LDH) released into the
supernatant of damaged cells. POH (0.5, 1, 1.5, 2, 2.5
and 4 mM), 4 mM PA and 0.5 mM ouabain were added
to specific wells. After 30 minutes or 24 hours incuba-
tion at 37°C, the supernatant was collected and the LDH
activity was measured by spectrophotometry at 510 nm.
As a control for the maximum LDH release, cells were
treated with 0.1% triton-X100 in DMEM medium for 30
min before running the assay. Some controls were per-
formed to define a possible interference of DMSO. The
cell viability in control samples (in the presence of DMSO
0.1%) was defined as 100% and the amount of viable cells
in the treated samples was expressed as a percentage of
those in the DMSO controls.
JNK and p38 phosphorylation
After 30 min incubation at 37°C, the cells were lysed in
buffer (11 mM Tris–HCl, 170 mM NaCl, Triton X-100
1%) containing protease and phosphatase inhibitor cock-
tail tablets (Roche). 6x sample buffer (containing 25 mM
Tris, 40 mL Glycerol (85% v/v), 28 mM SDS, 20 mL β-
mercaptoethanol and 120 mg Bromophenol blue) was
added. The cell lysates were clarified by centrifugation
and the supernatant was used for western blot analysis.
The total protein concentrations were determined by the
Bradford method [36].
The total protein content (50 μg) was loaded in each
lane and separated using 10% SDS-PAGE electrophor-
esis. The bands were detected using chemilumines-
cence (Kit Amersham™ ECL™Prime Western Blotting
Detection Reagent; GE) with an X-ray film (Hyperfilm
ECL; GE) and quantified using the Image Master 2D
Elite 4.01 (GE). The band densitometric measurements
were normalized to the corresponding SAPK/JNK1/2
or p38 MAPK levels, with the control samples set to 1.
Treatment values were then expressed relative to the
control levels. The primary antibodies used were mono-
clonal anti-phospho-SAPK/JNK1/2 and anti-SAPK/
JNK1/2 (1:1000; Cell Signaling; ordering numbers
#4671S and #9258S, respectively) and anti-phospho-
p38MAPK (1:500) and anti-p38MAPK (1:1000; Cell
Signaling, ordering numbers #4511 L and #9212 L,
respectively). The U87 cells were also pretreated for
30 minutes with 10 nM dasatinib (LC Laboratories) and7.5 mM β-cyclodextrin (Sigma). After this pretreat-
ment, the cells were treated with POH.
Determination of cytokine levels
U87 and U251 cells were treated with POH (0.5 and
1.5 mM), ouabain (1 μM) or lipopolysaccharide (LPS -
5 μg/mL) from Escherichia coli (O127:B8 - Sigma) for 1,
6 and 24 hours. The supernatants were analyzed for
interleukin production (IL-1β, IL-6 and IL-8) and tumor
necrosis factor (TNFα) using the specific monoclonal
antibodies of the Immunoassay kit (R&D Systems)
according to the manufacturer’s protocols.
Cell death assay
U87 and U251 cells were pretreated for 30 minutes with
JNK inhibitor V [1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)
ethyl)amino)-4-pyrimidinyl)acetonitrile; Calbiochem], an
inhibitor of JNK1/2 activation, before treatment with
0.5 mM POH and 0.5 mM POH plus 0.5 μM JNK inhibi-
tor V. After 24 hours of incubation, the cells were sus-
pended in annexin and propidium iodide binding buffer as
specified in the TACS Annexin V-FITC apoptosis detec-
tion kit (R&D Systems). The samples were analyzed using
a BD Accuri C6 flow cytometer (BD Biosciences). The BD
Accuri software was used to determine the Annexin V-
positive apoptotic cells.
Caspase-3 activation
U87 and U251 cells were treated for 24 hours with
0.1% DMSO or 0.5 μM JNK inhibitor V (control
groups) and 0.5 mM POH or 0.5 mM POH plus
0.5 μM JNK inhibitor V. The cells that received JNK
inhibitor V were pretreated with this inhibitor for
30 minutes before treatment. After 24 hours of incuba-
tion, the cells were fixed with 4% paraformaldehyde for
15 min. After this period, the cells were extensively
washed in PBS (phosphate buffered saline) and unspe-
cific sites were blocked with 3% bovine serum albumin
(BSA), 5% normal goat serum (NGS) and 0.2% Triton
X-100 (Vetec) diluted in PBS for 1 hour before immu-
noreactions with the following primary antibody:
rabbit anti-cleaved caspase-3 (1:100, Cell Signaling).
After 12 hours, the cells were thoroughly washed with
PBS and incubated with secondary antibodies for
2 hours at room temperature. The secondary antibody
was Alexa Fluor 488 (goat anti-rabbit IgG, Molecular
Probes; 1:300). The nuclei were counterstained with
DAPI (4’,6-diamidino-2-phenylindole, dilactate; Sigma).
Glass coverslips were mounted on glass slides using Far-
amount mounting media (DakoCytomation). The stained
cells were visualized using a fluorescent optical micro-
scope Nikon TE3000. The number of cells was analyzed
using the Image J software. At least 2000 cells were ana-
lyzed per experimental condition.
Figure 2 The effect of POH on cell viability. U251 and U87 cells, VERO cells and mouse astrocytes were treated with POH (0.5 - 4 mM) for 24 hours
and the LDH activity was quantified. Each point represents the means ± SD from at least three different experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs.
control group (0.1% DMSO), analyzed by Student’s t-test.
Figure 1 The effect of POH on the activity of NKA in the U251 and U87 cell lines, VERO cells and mouse astrocytes. Cells were treated with POH
(0.5 - 4 mM) for 30 minutes. The NKA activity was expressed as the difference between the Rb+ uptake in the absence or presence of 0.5 mM
OUA. Each point represents the means ± SD from at least four different experiments conducted in triplicate.
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Prism 5.0 software (GraphPadInc, CA, USA) was used
for graphical presentation and statistical analysis. The
statistical analyses included Student’s t-test and One-
way ANOVA followed by Newman-Keuls test. The
data are expressed as the means ± standard deviation
of at least three independent experiments. Significance
was determined at P < 0.05.Results
POH and PA effect on NKA activity
NKA activity in tumor and non-tumor cells was
based on the incorporation of Rb+ by cells in the ab-
sence and presence of ouabain (OUA) 0.5 mM. NKA
activity, which was expressed as the difference be-
tween Rb+ incorporation in the absence or presenceFigure 3 The effects of POH on the activation of JNK1/2 in U87 and U251
POH for 30 minutes. The graph shows the densitometric analysis of p-JNK1/2 re
band densities from western blots of p-JNK1/2 and total JNK1/2 corrected for c
The graph represents the means ± SD from at least three different experi
DMSO), analyzed by Student’s t-test.of 0.5 mM OUA, was inhibited by POH (0.5, 1, 1.5, 2,
3 and 4 mM) in a dose-dependent manner (Figure 1).
The IC50 values in the U251 and U87 cell lines were
1.8 and 2 mM, respectively. For the non-tumor cell
lines VERO and mouse astrocytes, the IC50 values
were 2.4 mM and 1.4 mM, respectively. Perillic acid
(PA) showed no effect on NKA activity in all cell lines
studied (Additional file 1).Cytotoxic effects of POH, PA and OUA after 30 min
incubation
Cells (U251, U87, VERO and mouse astrocytes) were
incubated for 30 minutes in the presence of POH, PA
and OUA. Cell death was determined by measuring the
LDH released in supernatant of treated and untreated
cell cultures. POH decreased significantly the cellcells, VERO cells and mouse astrocytes. The cells were treated with
lative to the total JNK1/2 and is shown in arbitrary units as the ratio of the
ontrol. The figures are representative of three independent experiments.
ments. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control group (0.1%
Garcia et al. Molecular Cancer  (2015) 14:105 Page 6 of 14viability only at 4 mM. Likewise, 0.5 mM OUA and
4 mM PA did not affect the cell viability after a 30 min
incubation period (Additional file 2).
Cytotoxic effects of POH and PA after 24 hours
incubation
The cytotoxic effects of POH and PA in human GBM
cells (U87 and U251) and non-tumor cells (VERO and
mouse astrocytes) were measured. The cells were treated
for 24 hours with different concentrations of POH (0.5,
1.5, 2.5 and 4 mM) and a high concentrations of PA
(4 mM). Cell viability was measured using the LDH
assay. The IC50 was 0.9 mM in VERO cells and 1.4 mM
in mouse astrocytes. In U251 and U87 cells, the IC50
values were 1.4 and 1.1 mM, respectively (Figure 2). PA
did not appreciably decrease the cell viabilities of any
studied cells (Additional file 3).
The effect of POH on JNK and p38 activation
U87 cells were treated for 30 min with increasing doses
of POH (0.1, 0.5 and 1.5 mM), which showed that POH
increased JNK1/2 phosphorylation in a dose-dependent
manner (Figure 3A). The same treatment was given to
the U251 cell line, but the experiments were performed
with 0.5 and 1.5 mM POH because 0.1 mM POH did
not produce a significant effect in the U87 cell line. 1.5 mM
POH significantly increased JNK1/2 phosphorylation in
U251 cells (Figure 3B). Similar results to those found with
U251 cells were obtained with mouse astrocytes, where
1.5 mM POH significantly increased JNK1/2 activation
(Figure 3C). In VERO cells, POH did not significantly in-
crease JNK1/2 activation (Figure 3D). The activation of p38Figure 4 The effects of dasatinib and methyl β-cyclodextrin on the activation
and 7.5 mM methyl β-cyclodextrin for 30 minutes. After the pretreatment, DM
expression of p-JNK1/2 and total JNK1/2 were detected by western blot. The
experiments. **p < 0.01 vs. control group (0.1% DMSO). ††p < 0.01, ‡‡p < 0.01
Student’s t-test.was assayed under the same conditions in the U87 cell line,
and 1.5 mM POH significantly increased p38 phosphoryl-
ation (Additional file 4).
The effects of methyl β-cyclodextrin and dasatinib on the
activation of JNK by POH
U87 cells were pretreated for 30 minutes with 10 nM
dasatinib and 7.5 mM methyl β-cyclodextrin. After this
time, the cells were treated for an additional 30 minutes
with 1.5 mM POH. The effects of POH on JNK1/2 acti-
vation were significantly reduced by both pretreatments
(Figure 4).The effect of POH on cytokine release
During the three incubation periods used, POH did not
alter the release of IL-1β, IL-6 and TNF-α in either of
the two human GBM cell lines. Similar results were ob-
served with IL-8 in both cell lines after 1 or 6 hours of
incubation (the values were below the lowest detection
limit of the ELISA kit used). On the other hand, an in-
crease in the release of IL-8 after 24 hours of incubation
with 1.5 mM POH was detected in the U251 cell line
(Figure 5).
The effect of JNK inhibition in the POH-mediated induction
of cell death
U87 and U251 cells were pretreated for 30 min with
0.5 μM JNK inhibitor V. Controls without the pretreat-
ment were also conducted. Then, the treatment was car-
ried out with the addition of 0.1% DMSO or 0.5 mM
POH either with or without 0.5 μM JNK inhibitor V forof JNK by POH in U87 cells. Cells were pretreated with 10 nM dasatinib
SO (0.1%) or POH (1.5 mM) was added. After 30 minutes incubation, the
data were expressed as the means ± SD from at least three different
vs. control group (1.5 mM POH without pretreatment), analyzed by
Figure 6 The effects of JNK inhibition on the induction of cell death by PO
and B) or with (C and D) JNK inhibitor V (0.5 μM) for 30 minutes. The cells
JNK inhibitor V (C), and 0.5 mM POH plus JNK inhibitor V (D). After 24 hours o
iodide and analyzed by flow cytometry. Figure 6E represents the percentage o
(right lower quadrant + right upper quadrant, respectively), which was calcula
means ± SD from at least three different experiments. ***p < 0.001 vs. control
inhibitor V), †p < 0.05 vs. control group (0.5 mM POH without the JNK inhibito
Figure 5 The effects of POH on the release of IL-8 in U251 cells. The cells
were treated with 0.1% DMSO, POH (0.5 and 1.5 mM) or different positive
controls (5 μg/mL LPS and 1 μM OUA) for 24 hours. An untreated control
was also carried out. IL-8 detection was performed using an Enzyme-Linked
Immunosorbent Assay (ELISA). The data were expressed as the means ± SD
from at least three different experiments. **p < 0.01; ***p< 0.001 vs. control
group (without treatment). †††p<0.001 vs. control group (0.1% DMSO),
analyzed by One-way ANOVA followed by Newman-Keuls test.
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Propidium iodide and annexin V-FITC fluorescence ana-
lysis revealed populations of viable and dead cells, as
shown in the respective quadrants (Figure 6 and 7). The
lower left quadrant shows the viable cells. The lower
right and upper right quadrant represent early apoptosis
and late apoptosis or necrosis, respectively. The upper
left quadrant represents necrosis.
U87 cells in the control group were treated only with
0.1% DMSO and are shown in Figure 6A. Treatment
with 0.5 mM POH (Figure 6B) showed a significant in-
crease in the dead cell population (71% ± 6.08) compared
to the control group. In addition, cell groups that were
pretreated with JNK inhibitor V (0.5 μM) and post-treated
with the same inhibitor plus 0.1% DMSO (Figure 6C) or
0.5 mM POH (Figure 6D) were evaluated. In this case,
36.4% (±2.05) of the cells died when treated with POH
plus JNK inhibitor V (Figure 6D). This value was higher
than the control group (Figure 6C), but significantly lower
than the rate of cell death in the POH-treated group
(Figure 6B). These results are shown in Figure 6E.
Using the U251 cell line, 0.5 mM POH also significantly
increased the cell death (71.2% ± 7.9) (Figure 7B) com-
pared to the control group (0.1% DMSO) (Figure 7A).H in U87 cells. Before treatment, U87 cells were incubated without (A
were treated with 0.1% DMSO (A), 0.5 mM POH (B) 0.1% DMSO plus
f incubation, the cells were stained with annexin V-FITC and propidium
f dead cells indicated by early apoptosis and late apoptosis or necrosis
ted from the data shown in Figures 6A-D. The data were expressed as the
group (0.1% DMSO), **p < 0.01 vs. control group (0.1% DMSO + JNK
r V), analyzed by Student’s t-test.
Figure 7 The effects of JNK inhibition on the induction of cell death by POH in U251 cells. Before treatment, U251 cells were incubated without
(A and B) or with (C and D) JNK inhibitor V (0.5 μM) for 30 minutes. The cells were treated with 0.1% DMSO (A), 0.5 mM POH (B) 0.1% DMSO
plus JNK inhibitor V (C), and 0.5 mM POH plus JNK inhibitor V (D). After 24 hours of incubation, the cells were stained with annexin V-FITC and
propidium iodide and analyzed by flow cytometry. Figure 7E represents the percentage of dead cells as indicated by early apoptosis and late apoptosis
or necrosis (right lower quadrant + right upper quadrant, respectively), which was calculated from the data shown in Figures 7A-D. The data were
expressed as the means ± SD from at least three different experiments. ***p < 0.001 vs. control group (0.1% DMSO), **p < 0.01 vs. control group (0.1%
DMSO + JNK inhibitor V). The difference between the treated group (0.5 mM POH+ JNK inhibitor V) and the control group (0.5 mM POH without the
JNK inhibitor V) was not statistically significant. The data were analyzed by Student’s t-test.
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approximately 52.6% (±8.02) cell death (Figure 7D).
This value was meaningful in comparison with the con-
trol group (Figure 7C) but insignificant when compared
to the POH-treated group (Figure 7B). These results
are presented in Figure 7E.
Induction of apoptosis by POH
U87 and U251 cells were treated with 0.5 mM POH and
0.5 mM POH plus 0.5 μM JNK inhibitor V for 24 hours.
The treatment was also carried out with the addition of
DMSO (0.1%) or JNK inhibitor V. Before treatment,
some groups of cells were pretreated with JNK inhibitor
V (0.5 μM) for 30 minutes. Cell death by apoptosis was
determined by immunocytochemistry.
POH-induced apoptosis in U87 and U215 cells are
shown Figure 8B and 9B, respectively. The cells were
immunostained for cleaved caspase-3 and the number of
positive cells was analyzed (8D and 9D). JNK1/2 inhib-
ition substantially reduced the amount of POH-induced
apoptosis (Figure 8C and 9C). The control conditions
are shown in Figures 8A and 9A. The addition of JNK
inhibitor V alone had no effect on cell death.Discussion
Perillyl alcohol (POH) has the ability to induce apoptosis
in cancer cells [37-40] and has been used in the therapy
of different tumors, including gliomas [31,32,41,42].
These effects of POH may be at least partly related to
the inhibition of NKA activity [28,43].
As a first step in studying the ability of POH to inhibit
glioma cell proliferation, we evaluated the NKA activity
based on the incorporation of Rb+ by tumor and non-
tumor cells. POH inhibited the NKA activity in a dose-
dependent manner. The IC50 values of U251 and U87
human GBM cell lines were similar and were very close
to the value previously found by our group using the
A172 human GBM cell line [28]. In these three human
GBM cell lines (U251, U87 and A172), POH completely
inhibited Rb+ uptake at 4 mM. In the non-tumor VERO
cell line, the IC50 was slightly higher and POH did not
reach 100% inhibition at 4 mM. These IC50 values were
not significantly different, which was expected because
kidney and GBM cells express the same α1 NKA iso-
form [23,44], against which POH has a higher degree of
selectivity [28]. Due to the unavailability of normal hu-
man astrocyte cultures, we used mouse astrocytes. In
Figure 8 POH-induced apoptosis in U87 cells. U87 in the control condition (Control, A). The cells were treated with 0.5 mM POH (POH, B) and
0.5 mM POH plus 0.5 μM JNK inhibitor V (POH + IJNK, C). After 24 hours, the cells were immunostained for cleaved caspase-3 and the number of
positive cells was analyzed (D). Whereas POH induced cell apoptosis, the addition of the JNK inhibitor completely inhibited this effect. The addition of
DMSO or JNK inhibitor V alone had no effect on cell death. Scale bar: 20 μm.*P < 0.050, analyzed by Student’s t-test.
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uptake. It is interesting to note that mouse astrocytes
mainly express the NKA α2 and α3 isoforms, which are
more sensitive to the inhibitory effects of POH [28,44].
Furthermore, perillic acid (PA), a metabolite produced
rapidly in the human body after POH administration,
was also tested. NKA activity was not affected by PA in
any of the cell lines used in this work. To assess
whether the inhibition of Rb+ uptake by cells (U251,
U87, VERO and mouse astrocytes) were caused by cell
death, cell viability experiments were carried out in the
presence of POH, PA and ouabain (OUA). The cell via-
bility was significantly decreased by POH only when a
high concentration was used. OUA and PA did notaffect the cell viability. Therefore, the decreased Rb+
uptake occurred through NKA inhibition and not due
to cell death.
Low plasma levels of POH cannot be measured accur-
ately, but the levels of their metabolites are detectable
due to the rapid degradation of POH [45]. Thus, POH
administration is more advantageous than the use of car-
diac glycosides because its rapid metabolism decreases
its undesirable adverse effects. Interestingly, therapeutic
doses of POH are far superior to those of cardiac glyco-
sides [46]. The cytotoxic properties of compounds that
may or may not be similar to cardiac glycosides but can
still affect NKA activity have already been tested [47-52].
Though PA did not affect the cell viability of the studied
Figure 9 POH-induced apoptosis in U251 cells. U251 in the control condition (Control, A). The cells were treated with 0.5 mM POH (POH, B) and
0.5 mM POH plus 0.5 μM JNK inhibitor V (POH + IJNK, C). After 24 hours, the cells were immunostained for cleaved caspase-3 and the number of
positive cells was analyzed (D). Whereas POH induced cell apoptosis, the addition of the JNK inhibitor completely inhibited this effect. The addition of
DMSO or JNK inhibitor V alone had no effect on cell death. Scale bar: 20 μm.*P < 0.050, analyzed by Student’s t-test.
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lines. The cell viabilities of both tumor and non-tumor
cells were significantly reduced at lower dose and in-
creased thereafter according to the POH dose. The IC50
value for POH was not significantly different between
cell types (U251 and U87). Similar results were obtained
by Cho et al. (2012) [53] using glioma cell lines U87,
U251 and LN229.
Due to its role in fundamental cellular functions such
as proliferation, differentiation and apoptosis, NKA has
been considered as a target for drugs, especially those
with antitumor activities [17,25,52]. Several studies have
reported the induction of apoptosis by cardiac glycosides
in various tumor cells [14,24,46,54-56]. At this point, itis important to emphasize that POH induces apoptosis
in various tumor cells, including gliomas. However, the
exact mechanism by which this drug induces apoptosis
is unclear [38,57]. It is known that POH preferentially
inhibits the NKA α1 isoform [28], which modulates
apoptosis, cell migration and proliferation and is overex-
pressed in the caveolae of GBM cells [26,27]. Consider-
ing these facts, we tested the activation of JNK, a main
protein target of the MAPK pathway controlling cell
growth and/or death [15].
The human GBM cells (U87 and U251) and non-
tumor cells (VERO cells and mouse astrocytes) were
treated with POH. POH increased JNK1/2 phosphoryl-
ation in the U87 and U251 cell lines that was similar
Garcia et al. Molecular Cancer  (2015) 14:105 Page 11 of 14to mouse astrocytes but not VERO cells. Studies with
fibroblasts have shown that JNK activation and the
pro-apoptotic protein Bax, a Bcl2 family member [58],
are sufficient to cause the caspase-independent release
of cytochrome c, which leads to apoptosis. Addition-
ally, POH increases the Bax expression in non-small
cell lung cancers [39,40]. Although JNK phosphoryl-
ation by POH has not yet been described, Satomi et al.
(1999) [59] showed that POH induces the increased
expression and phosphorylation of c-Jun protein in
breast cancer cells, which is involved in cellular prolif-
eration and apoptosis. This phosphorylation occurred
quickly at the N-terminal site of c-Jun, which is nor-
mally phosphorylated by JNK. According to these re-
searchers, c-Jun activation by POH in these cells may
represent a relevant early response to apoptosis. Thus,
POH seems to modulate the JNK signaling cascade
[59]. In addition, the activation of p38, another protein
of the MAPK family, was observed in U87 cells, broaden-
ing the framework of intracellular signaling proteins in-
volved in POH-induced cell death. With respect to JNK
and p38 activation in GBM cells, it was recently reportedFigure 10 A schematic diagram showing the possible relationship betwee
connection of POH to the NKA-Src complex in the signalosome leads to
disruption (by methyl β-cyclodextrin) blocked the phosphorylation of JN
caspase-3. JNK inhibition (by the JNK inhibitor V) decreased the inducti
has not been described in the literature but an increase in the release o
findings of this study, whereas the dashed line show the known molecu
Kinase; JNK: c-Jun N-terminal Kinase; and IL-8: Interleukin 8.that piperlongumine, an alkaloid with lipophilic properties
found in plants of the species Piper longum L., can activate
JNK and p-38 MAPKs, leading to apoptosis of U87,
LN229 and 8MG-BA GBM cell lines through the accumu-
lation of reactive oxygen species [60].
To correlate the POH induced-JNK phosphorylation
with NKA, we evaluated JNK activation in the presence
of the Src kinase inhibitor dasatinib [61] and methyl β-
cyclodextrin, a molecule that extracts cholesterol from
the plasma membrane, disrupting lipid rafts [62] and
thus blocking the MAPK pathway in the signalosome,
which is a caveolae microdomain in which the formation
of the NKA-Src complex occurs. NKA mediated-cellular
signaling is initialized in the cholesterol and sphingo-
myelin-rich plasma membrane subfractions of the caveolae,
in which the NKA α1 subunit interacts with various signal-
ing proteins. Src is a primary target of the NKA α1 subunit
and is responsible for communication between NKA and
other proteins. When the NKA-Src complex is activated,
different signaling pathways, including the MAPK path-
ways, are initiated in a specific manner depending on the
stimulus and cell type [7,63]. In U87 cells, the effect ofn apoptosis in Glioblastoma cells and the NKA-Src-JNK pathway. The
the activation of JNK. Src inhibition (by dasatinib) and caveolae
K. JNK activation can induce apoptosis through cleavage of
on of apoptosis. The JNK-mediated production of IL-8 in GBM cells
f IL-8 might favor tumor progression. The solid lines indicate the
lar mechanisms. POH: Perillyl alcohol; NKA: Na/K-ATPase; Src: Src
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dasatinib and methyl β-cyclodextrin pretreatment. Both
pretreatments appeared to prevent NKA activation in
the signalosome. These results support our hypothesis
that NKA is directly involved in mechanisms involving
POH-mediated JNK activation in human GBM cells,
triggering cell death through the activation of NKA in
the signalosome.
Activated MAPKs are able to mediate the release of
interleukin (IL) [64] and can be induced by cardiac gly-
cosides through NKA in cytotrophoblast embryonic cells
[15]. However, POH suppressed the level of pro-
inflammatory cytokines in ischemia-reperfusion injury in
rat brains [65]. In GBM, the presence of pro-inflammatory
cytokines is associated with tumor growth and hence
with its malignancy. IL-6 induces the proliferation of
tumor cells proliferation, whereas IL-8 has angiogenic
and chemotactic properties [66]. During the three in-
cubation periods used (1, 6 and 24 hours), POH did
not alter the release of pro-inflammatory cytokines in
either of the two human GBM cell lines. On the other
hand, an increase in the release of IL-8 after 24 hours
of incubation with POH was detected in the U251 cell
line. Cho et al. (2012) [53] found a decrease in the
release of IL-8 in U87 cells after 48 hours of incubation
using 0.6 mM POH. Since IL-8 enhances GBM invasion
[67,68], this increase may be a strategy used by the
cells in circumventing the POH-induced effects on cell
death.
POH showed a significant increase in early and late
apoptosis or necrosis of U87 and U251 cells, but when
these cells were pretreated with a JNK inhibitor, a sig-
nificant decrease in cell death was found. Our results in
the U251 and U87 human GBM cell lines showed that
the inhibition of JNK activation decreased the effects
caused by POH, demonstrating the possible involvement
of JNK in the induction of apoptosis in GBM cells. How-
ever, the reduction in the POH-induced cell death did not
occur to the same extent in both cell lines. Interestingly,
in addition to this difference in the rates of blocked cell
death between these tumor cell lines, the effect of POH on
the activation of JNK was also lower in the U251 cells, as
previously shown. Since the same intensity of cell death
was induced by POH in both GBM cell lines, part of this
pathway might be JNK-independent in U251 cells. It is
possible that the activation of other MAPKs or the in-
volvement of the PI3K/Akt pathway are also linked to the
NKA-Src complex [62,68].
Human GBM cells are driven to undergo apoptosis
when treated with POH [38,57]. As shown previously,
JNK activation appears to be involved in this phenomenon.
To confirm the involvement of apoptosis in POH-mediated
cell death, U87 and U251 cells were treated with POH or
POH plus JNK inhibitor V and then were immunostainedfor cleaved caspase-3. As expected, POH induced apoptosis
in GBM cells, though interestingly, JNK inhibition de-
creased the POH-induced apoptosis. NKA, especially
the α1 isoform, plays an important role in GBM sur-
vival [26,27]. Inhibitors of this enzyme, particularly the
cardiac glycoside UNBS1450 and the monoterpene
POH, cause death in these tumor cells by autophagy
and apoptosis induction, respectively [26,38]. However,
the mechanisms triggering apoptosis were not com-
pletely elucidated [38].
Conclusions
Together, our data lead to the following proposed
mechanism for the action of POH in tumor glial cells
(Figure 10): the connection between POH and NKA
present in the signalosome could stimulate the Src kin-
ase, leading to signaling via the MAPK signaling cas-
cade and subsequent activation of JNK and p38.
Activated JNK could induce apoptosis through different
molecular mechanisms, including caspase-3 activation.
Although JNK-mediated IL-8 production in GBM cells
has not been described in the literature, we observed
an increase in the release of this cytokine in U251 cells,
which may favor tumor progression. This hypothesis is
supported by our observation that 1) Src inhibition and
caveolae disruption blocked the phosphorylation of
JNK, and 2) the induction of apoptosis was reduced by
JNK inhibition. Here, we demonstrate that the caveolar
NKA-Src complex signals through JNK and caspase-3
activation during the POH-induced apoptosis of human
GBM cells.Additional file
Additional file 1: The effect of PA on the activity of NKA in the
U251 and U87 cell lines, VERO cells and mouse astrocytes. Cells
were treated with 4mM PA for 30 minutes. The NKA activity was
expressed as the difference between the Rb+ uptake in the absence or
presence of 0.5 mM OUA. Each point represents the means ± SD from at
least four different experiments conducted in triplicate.
Additional file 2: The effect of POH, PA and OUA on cell viability.
U251 and U87 cells, VERO cells and mouse astrocytes were treated with
POH (0.5 - 4 mM), 4mM PA and 0.5mM OUA for 30 minutes and the LDH
activity was quantified. Each point represents the means ± SD from at
least three different experiments. ***p<0.001 vs. control group (0.1% DMSO),
analyzed by Student’s t-test.
Additional file 3: The effect of PA on cell viability. U251 and U87
cells, VERO cells and mouse astrocytes were treated with 4mM PA for 24
hours and the LDH activity was quantified. Each point represents the
means ± SD from at least three different experiments.
Additional file 4: The effects of POH on the activation of p38 in
U87 cells. The cells were treated with POH for 30 minutes. The graph
shows the densitometric analysis of p-p38 relative to the total p38 and is
shown in arbitrary units as the ratio of the band densities from western
blots of p-p38 and total p38 corrected for control. The figures are
representative of three independent experiments. The graph
represents the means ± SD from at least three different experiments.
**p<0.01 vs. control group (0.1% DMSO), analyzed by Student’s t-test.
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